IDiyas

For the Inventor, By the Inventor

Allschwil, Switzerland

Paul Wenk

USPTO Granted Patents = 9

Average Co-Inventor Count = 3.3

ph-index = 5

Forward Citations = 54(Granted Patents)


Company Filing History:

goldMedal9 out of 6,850 
 
Ciba-geigy Corporation
 patents

Years Active: 1984-1991

Loading Chart...
9 patents (USPTO):
1. 5032606 - Novel fluorinated resorcinol ethers and their use as anti-allergics and (1991-07-16),
2. 4863942 - Novel resorcinol ethers and anti-inflammatory and anti-allergic use (1989-09-05),
3. 4820726 - Oxaloamino substituted fluorinated resorcinol ethers and anti-allergic (1989-04-11),
4. 4808604 - N-(substituted phenyl) tetrazol-5-yl carboxamides and anti-allergic use (1989-02-28),
5. 4670604 - Novel fluorinated resorcinol ethers (1987-06-02),
6. 4558043 - Heterocyclicamino containing benzofurans and 2,3-dihydrobenzofurans, (1985-12-10),
7. 4514415 - Benzofuran-2(3H)-ones used as anti-inflammatory agents (1985-04-30),
8. 4451462 - Method of treating inflammation and pain using heteramino benzofurans (1984-05-29),
9. 4426380 - Benzofuran-2-ones and pharmaceutical compositions (1984-01-17),

Title: Paul Wenk: Innovator in Anti-Allergic and Anti-Inflammatory Compounds

Introduction

Paul Wenk is a notable inventor based in Allschwil, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-allergic and anti-inflammatory compounds. With a total of 9 patents to his name, Wenk's work has had a considerable impact on medical science.

Latest Patents

Wenk's latest patents include innovative compounds such as novel fluorinated resorcinol ethers and their use as anti-allergics. These compounds exhibit properties that can alleviate allergic reactions and inflammation. Another significant patent involves 4-acylresorcinol ethers, which have been shown to possess LTD4-antagonistic and PLA2-phospholipase-inhibiting properties. These compounds are designed to be manufactured using established methods, ensuring their viability for pharmaceutical applications.

Career Highlights

Throughout his career, Wenk has been associated with Ciba-Geigy Corporation, a prominent player in the pharmaceutical industry. His work has focused on creating compounds that address critical health issues, particularly those related to allergies and inflammation. His innovative approach has led to the development of several key patents that are recognized in the scientific community.

Collaborations

Wenk has collaborated with esteemed colleagues such as Andreas Beck and Alfred Sallmann. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas, further enhancing the quality of their research and development efforts.

Conclusion

Paul Wenk's contributions to the field of pharmaceuticals through his innovative patents have established him as a key figure in the development of anti-allergic and anti-inflammatory treatments. His work continues to influence the medical community and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…